# Achilles Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/achilles-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.achillestx.com
- Total disclosed funding: $193M
- Latest round: Series C (Nov 19, 2020)
- Investors on record: 8

## About

Achilles Therapeutics Ltd, based in the UK, focuses on pioneering immuno-oncology therapies that harness the body's immune system to fight cancer. Their innovative approach aims to improve treatment outcomes for patients with solid tumors.Founded in 2016 in London, UK, Achilles Therapeutics Ltd is dedicated to developing personalized cancer therapies. The company has not undergone any significant changes in business strategy. Sergio Quezada is a key founder, leading the firm as it has undertaken 5 deals since inception. The most recent funding round, an IPO, raised USD 175.50 mn, matching the total amount raised to USD 175.50 mn.Achilles Therapeutics specializes in innovative immuno-oncology therapies designed to enhance the body's ability to combat cancer. Their primary offerings focus on personalized treatments that target specific mutations within tumors, helping to tailor therapy to individual patients. The company primarily serves healthcare institutions and organizations involved in cancer treatment, ensuring that patients benefit from customized therapeutic options based on their unique tumor profiles.The financial results for 2023 indicate an EBITDA of USD -76.25 mn. Achilles Therapeutics generates revenue through strategic partnerships and collaborations within the healthcare sector, capitalizing on the growing demand for personalized medicine in oncology.Achilles Therapeutics plans to advance its pipeline of personalized cancer therapies, with new product launches aimed for 2024. The company is targeting expansion into North American markets, specifically focusing on key treatment centers for oncology. Recent funding from MaasInvest will support these initiatives, enabling the development of their innovative therapies and broadening their market reach.

## Funding rounds

- Series C, Nov 19, 2020, $70M — OrbiMed Advisors, Invus [DUP], Forbion, Redmile Group, Syncona, RA Capital Management, Perceptive Advisors, Boxer Capital
- Series B, Sep 3, 2019, $123M — Invus [DUP], Forbion, Redmile Group, Syncona, RA Capital Management, Perceptive Advisors

## Investors

- Invus [DUP] — Series B, Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B, Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C
- Syncona (https://capitalatlas.ai/funds/syncona) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C